
Reaching over JPY 1 billion in corporate valuation
Surpassing JPY 1 billion in corporate valuation upon completion of Seed 4 fundraise
ブログ
Surpassing JPY 1 billion in corporate valuation upon completion of Seed 4 fundraise
JPY 250 million raised from the existing investors to support a pre-clinical and clinical studies
Dr. Kambayashi’s research published in the journal Science (Vol. 373, Issue 6554)
Establishment of Abrax Australia Pty. Ltd. for execution of clinical trials in Australia
A new formulation produced by Tergus Biopharma and code-named “ABX-919”
JPY 50 million raised from private investors
Initiation of new drug formulation with Tergus Biopharma through business partnership
Establishment of a regulatory strategy team for new drug approval through business partnership
¥190 million raised from a venture capital and private investors
A corporation established in Japan with Seed 1 funding